Brokerages Set Roivant Sciences Ltd. (NASDAQ:ROIV) PT at $17.93

Roivant Sciences Ltd. (NASDAQ:ROIV) has earned an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $17.93.

ROIV has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, Bank of America upped their price objective on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00. Following the completion of the sale, the chief operating officer now owns 606,525 shares of the company’s stock, valued at approximately $6,865,863. This trade represents a 14.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CIO Mayukh Sukhatme sold 185,946 shares of the business’s stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total transaction of $2,231,352.00. Following the sale, the executive now owns 18,836,547 shares in the company, valued at $226,038,564. The trade was a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,942,629 shares of company stock valued at $23,071,486. 7.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ROIV. Mutual of America Capital Management LLC increased its stake in Roivant Sciences by 0.4% in the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock valued at $3,457,000 after purchasing an additional 1,142 shares in the last quarter. GAMMA Investing LLC grew its holdings in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after purchasing an additional 1,288 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Roivant Sciences by 23.2% in the second quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after buying an additional 1,603 shares in the last quarter. Covestor Ltd increased its position in shares of Roivant Sciences by 9.1% in the third quarter. Covestor Ltd now owns 19,190 shares of the company’s stock valued at $222,000 after buying an additional 1,605 shares in the last quarter. Finally, US Bancorp DE raised its stake in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Trading Up 0.1 %

Shares of ROIV opened at $11.52 on Friday. The company’s 50 day simple moving average is $11.91 and its 200-day simple moving average is $11.58. The firm has a market cap of $8.39 billion, a PE ratio of 2.04 and a beta of 1.27. Roivant Sciences has a 12-month low of $9.69 and a 12-month high of $13.06.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.